News
also known as TIM-3, in combination with AstraZeneca's anti-PD-L1 mAb IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC）in China. BioCity will lead the trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback